December 21, 2005
Flamel Announces GlaxoSmithKline Submission of NDA for Micropump-Enabled, Currently Marketed GSK Drug

October 26, 2005
Flamel Technologies Announces Third Quarter Results

October 26, 2005
Flamel Technologies Announces Successful Phase III Results in Connection with its Collaboration with GlaxoSmithKline

October 24, 2005
Flamel Technologies Announces Election of New Members of the Board of Directors; Results of Extraordinary General Meeting

October 21, 2005
Flamel Technologies Announces Projected Release Date of Third Quarter Results, Conference Call

October 06, 2005
Flamel Technologies Appoints Michel Finance as Chief Financial Officer

September 23, 2005
Flamel Technologies Announces Positive Preliminary Results of a Phase I/II Trial of IFN-alpha-XL in Patients with Chronic Hepatitis C Virus Infection

September 22, 2005
Flamel Technologies Announces New Nominees for Board of Directors, Extraordinary General Meeting

September 19, 2005
UBS Global Life Sciences Conference to Webcast Flamel Technologies Corporate Presentation

September 5, 2005
Flamel Technologies announces notification of termination of the license of Flamel's Micropump® Technology to TAP Pharmaceutical Products Inc. for Lansoprazole

July 27, 2005
Flamel Technologies Announces Second Quarter Results

July 21, 2005
Flamel Technologies Announces Projected Release Date of Second Quarter Results, Conference Call

June 22, 2005
Flamel Technologies announces election of new board at annual meeting of shareholders

June 14, 2005
Flamel announces patent filing for Trigger Lock™ System to Prevent Opioid Misuse and Abuse

June 13, 2005
Flamel Technologies Announces patent filing for ''combination of Asacard with COX-2 inhibitors''

May 5, 2005
Flamel Technologies Announces First Quarter Results, Including Milestone from TAP Pharmaceuticals
Webcast


April 29, 2005
Flamel Technologies Announces Announces Projected Release Date of First Quarter Results, Conference Call
A conference call to discuss its first quarter financial results has been scheduled for Friday, May 6th at 8:30 AM (ET). To participate in the conference call, investors in the US and Canada are invited to dial 1-800-374-1498. International callers are invited to call 1-706-634-7261. The Conference ID # is 5840434.

March 11, 2005
Flamel Technologies Announces Fourth Quarter and Year-End Results
Webcast
A conference call to discuss this matter has been scheduled for Monday morning, March 14th at 8:30 am EST. The dial-in number for the conference call is 800 374-1498 in the United States and Canada. International callers should dial 706-634-7261.

March 7, 2005
Flamel Technologies Announces Results of Meeting of Shareholders; Sets Projected Release Date for 2004 Results and Conference Call

March 3, 2005
Flamel Technologies Announces Termination of Licensing Agreement for Genvir® and Recovery of Rights
Webcast
The replay from the conference call Friday morning, March 4th at 8:30 am EST is now available. The dial-in number for the replay is 800 642-1687 in the United States and Canada. International callers should dial 706-645-9291.

February 7, 2005
Flamel Technologies Announces Public Release of Phase IIa Data on Basulin®

January 31, 2005
Flamel Technologies Announces Payment from Bristol-Myers Squibb to Flamel as well as Recovery of Rights to Data, including Phase IIa Results

January 26, 2005
Flamel Technologies Announces New Composition of its Scientific Advisory Board